Synopsis : Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F.…
Synopsis : Shares of Madrigal Pharmaceuticals went up in premarket trading after the company announced positive topline data from its Phase III…
Summary : One week after Johnna Rossell departed Biogen for Enzyvant, the embattled company announced that two members of its board of…
Synopsis : Biogen is selling its nearly 50% stake in South Korea-based Samsung Bioepis for $2.3 billion. The move will provide Biogen…
Courtesy of Alzamend Neuro On the strength of data from its Phase 1 Study of lead compound, AL001, being developed for…
Summary : Oxford Biomedica and Homology Medicines to establish Oxford Biomedica Solutions LLC, a new U.S.-based AAV Manufacturing and Innovation Business Homology…
Summary : The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed…
Synopsis : The National Institutes of Health (NIH) is awarding $170 million over five years, pending the availability of funds, to clinics…
Summary : Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins Company moving to full enrollment pending independent safety review…
Summary – Lupin Diagnostics, a 100 percent subsidiary of Lupin Limited, has set up a state-of-the-art 45,000 sq. ft National Reference Laboratory…